Clinical trial · ClinicalTrials.gov
A Study to Evaluate the Effect of CagriSema on Body Weight in Adults Living With Overweight or Obesity
NCT05929066
Trial identity
- Registry
- ClinicalTrials.gov
- Registry ID
- NCT05929066
- Phase
- Phase 3
- Design
- Interventional
- Allocation
- Randomized
- Masking
- Double-blind
- Overall status
- Active, not recruiting
- Result status
- none
Sponsors & collaborators
- Sponsor
- Novo Nordisk
- Collaborators
- —
Intervention assets
Arms
| Arm | Intervention | Enrollment |
|---|---|---|
| Cagrisema | cagrilintide + semaglutide once weekly | — |
| Semaglutide | semaglutide once weekly | — |
| Cagrilintide | cagrilintide once weekly | — |
| Placebo | placebo once weekly | — |
Population & enrollment
- Population summary
- Adults with overweight or obesity.
- Eligibility summary
- BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity.
- Planned enrollment
- 3000
- Actual enrollment
- 3000
Endpoints
- Primary endpoint
Percent change in body weight from baseline at week 68
- Secondary endpoint
Proportion achieving ≥5%, ≥10%, ≥15%, ≥20% weight loss
Dates
- Start date
- Jul 13, 2023
- Primary completion
- Jul 1, 2025
- Completion date
- Dec 1, 2025
- Last synced
- Aug 15, 2024
Locations
- Multiple countries
Plain-language interpretation
A Study to Evaluate the Effect of CagriSema on Body Weight in Adults Living With Overweight or Obesity is a Phase 3 Interventional sponsored by Novo Nordisk. It is evaluating Semaglutide and Cagrisema in Adults with overweight or obesity.. The primary endpoint is Percent change in body weight from baseline at week 68.
Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against ClinicalTrials.gov.
Sources
- registryprimary record
REDEFINE 1: Cagrisema for weight management in adults with overweight or obesity
Novo Nordisk A/S · ClinicalTrials.gov · Jul 13, 2023 · NCT05929066